S. Desolms

发表

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

A. Kral, J. Davide, N. Kohl, 1995, Nature Medicine.

Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.

N. Kohl, R. Gomez, N. Anthony, 1994, Proceedings of the National Academy of Sciences of the United States of America.

P450 interaction with farnesyl-protein transferase inhibitors metabolic stability, inhibitory potency, and P450 binding spectra in human liver microsomes.

C. Tang, J. Lin, J. Wai, 2001, Biochemical pharmacology.

Farnesyltransferase inhibitors and anti-Ras therapy

N. Rosen, N. Kohl, L. Sepp-Lorenzino, 2005, Breast Cancer Research and Treatment.

A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site.

T. Halgren, M. Holloway, J. Vacca, 1995, Journal of medicinal chemistry.

2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution.

A. Deana, C. Sweet, G. Stokker, 1980, Journal of medicinal chemistry.

Potent, non-thiol inhibitors of farnesyltransferase.

D. Pompliano, S. Graham, J. Hutchinson, 1998, Bioorganic & medicinal chemistry letters.

Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.

A. Kral, D. Heimbrook, J. Davide, 2001, Cancer research.

Synthesis of the taxane diterpenes: Construction of a bc ring intermediate for taxane synthesis

S. J. Desolms, C. Swindell, S. Desolms, 1984 .

Pseudodipeptide inhibitors of protein farnesyltransferase.

N. Kohl, E. Rands, D. Pompliano, 1995, Journal of medicinal chemistry.

Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.

A. W. Shaw, T. Ciccarone, L. Beese, 2003, Journal of medicinal chemistry.

The total synthesis of myo-inositol polyphosphates

J. Huff, J. Vacca, D. Billington, 1989 .